Evidence map›Paper›PMID 28976299›Full record

ArticlePharmacogenomics2017

Variation in the α

Vivian K Kawai, Rebecca T Levinson, Abiodun Adefurin, Daniel Kurnik, Sarah P Collier, Douglas Conway, Charles Michael Stein

Open access · greenAbstract read
In one paragraph

Article in Pharmacogenomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. TGFBR2 coordinates the endometrial response to estrogen, regulating endometrial hyperplasia and fertility.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Vivian K KawaiDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Rebecca T LevinsonVanderbilt Genetics Institute, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Abiodun AdefurinDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Daniel KurnikDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Sarah P CollierVanderbilt Institute for Clinical & Translational Research, Vanderbilt University Medical Center, Nashville, TN 37203, USA.
Douglas ConwayVanderbilt Institute for Clinical & Translational Research, Vanderbilt University Medical Center, Nashville, TN 37203, USA.
Charles Michael SteinDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Vanderbilt University Medical Center · USMeharry Medical College · USTechnion – Israel Institute of Technology · ILVanderbilt Health · US

Funding

The RCMI Program in Health Disparities Research at Meharry Medical College - SupplementU54MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI Samuel Evans Adunyah, JAMES E HILDRETH · 2017 to 2026
$48.2M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Structural genomics of norepinephrine transportersP01HL056693 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BIAGGIONI, ITALO · 1997 to 2016
$30.8M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4M
Training Program on Genetic Variation and Human PhenotypesT32GM080178 · NIGMS · VANDERBILT UNIVERSITY · PI COX, NANCY J, SAMUELS, DAVID C · 2007 to 2021
$3.1M
Automated Storage and Retrieval of Biological SystemsS10RR025141 · NCRR · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2008 to 2008
$988k
Pharmacogenetic Determinants of Variability in Response to GlucocorticoidsK23GM117395 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KAWAI, VIVIAN K · 2015 to 2018
$736k
NCATS NIH HHS UL1 TR000445NCRR NIH HHS S10 RR025141NHLBI NIH HHS P01 HL056693NIGMS NIH HHS K23 GM117395NIGMS NIH HHS T32 GM007569NIGMS NIH HHS T32 GM080178NIMHD NIH HHS U54 MD007586
6 · The paper itself

Abstract

aimSympathetic activation suppresses insulin secretion via pancreatic ADRA2A.  Because sympathetic activity and insulin demand increase during pregnancy, we tested the hypothesis  that ADRA2A variants are associated with gestational diabetes (GDM). PATIENTS &

methodsAmong Caucasian pregnant women without pre-existing diabetes, we genotyped 458 who had GDM and 1537 without GDM for seven ADRA2A variants.

resultsrs1800038 (OR: 2.34; p = 0.020) and rs3750625 (OR: 1.56; p = 0.010) increased the risk of GDM, and rs11195418 decreased it (OR: 0.62; p = 0.025). The associations remained significant after adjustment for maternal age, maternal BMI, parity and a genetic risk score that included variants previously associated with Type 2 diabetes mellitus and GDM.

conclusionADRA2A genetic variation contributes independently to the risk of GDM in Caucasian women.

Indexed as

AdultAllelesDiabetes, GestationalDiabetes Mellitus, Type 2FemaleGenetic Predisposition to DiseaseGenetic VariationGenotypeHumansInsulinPregnancyReceptors, Adrenergic, alpha-2Risk FactorsWhite PeopleADRA2A protein, humanInsulinReceptors, Adrenergic, alpha-2ADRA2A variantsCaucasiansgestational diabetes

Identifiers

PMID28976299
PMCPMC5694018
OpenAlexW2761199400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.